Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...
Halozyme Therapeutics (NASDAQ:HALO) executives highlighted what they described as a “significant and value-creating” 2025, ...
As I look back on the past year, it is clear that 2025 was one of the most significant and value-creating years in Halozyme ...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026 Halozyme Therapeutics, Inc.
Company Announcement COPENHAGEN, Denmark; February 17, 2026 - Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025 ...
Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billionFull Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results